A Pragmatic Study of MRD-Guided Maintenance for Multiple Myeloma in Latin America
Applicability of MRD to Tailored Maintenance in Multiple Myeloma: A Pragmatic Prospective Multicenter Study in Latin America
This prospective, pragmatic, multicenter study aims to evaluate the clinical and quality-of-life outcomes of discontinuing maintenance therapy in newly diagnosed MM patients with sustained MRD negativity for two years. By implementing a structured active surveillance strategy with serial MRD and QoL assessments, this study seeks to determine whether treatment-free intervals can be safely achieved without compromising survival outcomes, while improving patient well-being and reducing financial burden.
If successful, this study will provide foundational evidence to support MRD-guided, individualized maintenance strategies in MM and will serve as a platform for future interventional trials in Latin America.
研究概览
地位
详细说明
Multiple myeloma is a blood cancer that can require long-term maintenance treatment, even after a very good response to initial therapy. Although maintenance treatment can help control the disease, continuing it for many years may cause side effects, affect quality of life, and create financial burdens. Measurable residual disease (MRD) testing can detect very small amounts of myeloma cells that may remain after treatment.
This prospective, multicenter study in Latin America will evaluate a strategy of stopping maintenance therapy in selected adults with newly diagnosed multiple myeloma who have achieved a complete or stringent complete response and have remained MRD-negative for at least two consecutive years while receiving maintenance therapy.
After maintenance therapy is discontinued, participants will be followed for 24 months through clinical assessments, MRD testing, and quality-of-life questionnaires every six months. Maintenance therapy will be restarted if MRD reappears or if clinical or biochemical criteria for disease relapse are met, according to the study protocol.
The main objective is to evaluate whether this strategy can be implemented safely and to measure the occurrence of MRD reappearance, disease relapse, or death within 24 months. Additional objectives include evaluating progression-free survival, overall survival, quality of life, time until maintenance therapy is restarted, and the feasibility of this approach across Latin American centers.
The study aims to generate evidence to help guide individualized maintenance treatment decisions for selected patients with multiple myeloma.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Yadith Karina Lopez Garcia, MD
- 电话号码:+52 81 8675 6718
- 邮箱:yadith.lopezgrc@uanl.edu.mx
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥18 years at the time of enrollment.
- Diagnosis of newly diagnosed multiple myeloma according to International Myeloma Working Group (IMWG) criteria.
- Achievement of complete response (CR) or stringent complete response (sCR) following first-line therapy, with or without autologous hematopoietic cell transplantation (auto-HCT).
- Receipt of maintenance therapy for a minimum of 12 months prior to screening.
- Sustained measurable residual disease (MRD) negativity documented by next-generation flow cytometry (NGF assay EuroFlow-based or equivalent): MRD negativity confirmed on at least two consecutive bone marrow assessments, separated by a minimum of 12 months, with assessments performed during ongoing maintenance therapy.
- Negative functional imaging prior to maintenance discontinuation, defined as no evidence of metabolically active focal lesions on PET/CT, performed during screening.
- Absence of extramedullary disease at the time of study entry.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Ability to comply with study procedures, including serial MRD and quality-of-life assessments.
- Provision of written informed consent prior to any study-specific procedures.
Exclusion Criteria:
- Evidence of MRD positivity by NGF at any assessment during screening.
- PET/CT-positive lesions suggestive of active myeloma at screening.
- Biochemical or clinical relapse at the time of screening, as defined by IMWG criteria.
- Prior progression while receiving maintenance therapy.
- Any uncontrolled medical condition or comorbidity that, in the investigator's judgment, would compromise patient safety or protocol compliance.
- Inability or unwillingness to adhere to protocol-defined follow-up and surveillance procedures.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:MRD-Guided Maintenance Discontinuation and Active Surveillance
Eligible participants will discontinue maintenance therapy after meeting the protocol-defined criteria, including sustained measurable residual disease (MRD) negativity for at least two consecutive years and no evidence of active disease on PET/CT. Participants will undergo active surveillance for 24 months, with clinical assessments, MRD testing, and health-related quality-of-life evaluations every six months. If MRD reappears or clinical or biochemical disease relapse criteria are met, maintenance therapy will be reinitiated according to the study protocol. All participants will receive the same intervention strategy, as this is a single-arm study. |
The intervention consists of discontinuing maintenance therapy in selected adults with newly diagnosed multiple myeloma who have achieved complete response or stringent complete response and sustained measurable residual disease (MRD) negativity for at least two consecutive years during maintenance therapy, with no evidence of active disease on PET/CT. Following discontinuation, participants will undergo active surveillance for 24 months, with clinical assessments, bone marrow MRD testing, and health-related quality-of-life evaluations every six months. MRD will be assessed using next-generation flow cytometry. Maintenance therapy will be reinitiated if MRD reappears or if clinical or biochemical disease relapse criteria are met, according to the study protocol. The strategy is evaluated prospectively in a single-arm, multicenter study across Latin America. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Strategy Failure Rate at 24 Months Following MRD-Guided Maintenance Discontinuation
大体时间:From maintenance discontinuation (baseline) through 24 months.
|
Strategy failure is defined as the first occurrence of any of the following events after maintenance discontinuation: (1) measurable residual disease (MRD) resurgence, defined as conversion from sustained MRD negativity to MRD positivity detected by next-generation flow cytometry (EuroFlow; sensitivity ≥10^-5); (2) clinical or biochemical relapse/progression according to IMWG criteria; or (3) death from any cause. The outcome will be measured as the proportion of participants experiencing at least one strategy failure event. |
From maintenance discontinuation (baseline) through 24 months.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Measurable Residual Disease-Free Survival (MRD-FS)
大体时间:From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to the first occurrence of MRD resurgence or death from any cause. MRD will be assessed using next-generation flow cytometry (EuroFlow; sensitivity ≥10^-5). MRD-FS will be estimated using the Kaplan-Meier method. |
From maintenance discontinuation through 24 months.
|
|
Treatment-Free Survival (TFS)
大体时间:From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to re-initiation of maintenance therapy or death from any cause, whichever occurs first. TFS will be estimated using the Kaplan-Meier method. |
From maintenance discontinuation through 24 months.
|
|
Progression-Free Survival (PFS)
大体时间:From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to documented clinical or biochemical disease progression according to IMWG criteria or death from any cause, whichever occurs first. PFS will be estimated using the Kaplan-Meier method. |
From maintenance discontinuation through 24 months.
|
|
Overall Survival (OS)
大体时间:From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to death from any cause. Overall survival will be estimated using the Kaplan-Meier method, with survival probabilities reported at 12 and 24 months. |
From maintenance discontinuation through 24 months.
|
|
Measurable Residual Disease (MRD) Resurgence Rate
大体时间:At months 6, 12, 18, and 24 after maintenance discontinuation.
|
Proportion of participants who convert from sustained MRD negativity to MRD positivity during follow-up, assessed by next-generation flow cytometry (EuroFlow; sensitivity ≥10^-5). |
At months 6, 12, 18, and 24 after maintenance discontinuation.
|
|
Time to Maintenance Therapy Re-initiation
大体时间:From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to the re-initiation of maintenance therapy, regardless of whether treatment is restarted due to MRD resurgence, clinical or biochemical relapse, or investigator discretion. |
From maintenance discontinuation through 24 months.
|
|
Change From Baseline in Health-Related Quality of Life Assessed by EORTC QLQ-C30
大体时间:Baseline and months 6, 12, 18, and 24.
|
Changes in health-related quality of life will be assessed using the EORTC QLQ-C30 questionnaire. |
Baseline and months 6, 12, 18, and 24.
|
|
Change From Baseline in Multiple Myeloma-Specific Quality of Life Assessed by EORTC QLQ-MY20
大体时间:Baseline and months 6, 12, 18, and 24.
|
Changes in multiple myeloma-specific health-related quality of life will be assessed using the EORTC QLQ-MY20 questionnaire. |
Baseline and months 6, 12, 18, and 24.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.